STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex...
Hence then, the article about ema validates indication extension application for aspaveli for treatment of c3g and primary ic mpgn was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN )
Also on site :
- LIVE: Watch friends and family cross the 2026 Chicago Marathon finish line
- In the 1940s, Howard Hughes bought the peak next to the Hollywood Sign to build a house for Ginger Rogers; in 2010 more than 100 acres of it became part of Griffith Park
- Laundry Sauce Is Teaming Up With This Luxury Fragrance Brand for a Limited-Edition Launch